This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study Of Real-Time 3D Imaging Catheter With CT/MRI Quality

SAN DIEGO, April 30, 2013 /PRNewswire/ -- Acutus Medical, Inc. (ACM or Company), an emerging developer and manufacturer of medical devices designed to provide real-time 3D cardiac electrical mapping based on dipole density for the treatment of cardiac arrhythmias, announced today that it has performed its First-In-Man clinical study of its cardiac catheter to provide highest-quality real-time 3D mapping of the human heart.


The first four patient procedures were performed by Principal Investigator Professor Mattias Duytschaever, MD, at Sint-Jan Hospital in Brugge, Belgium.

"We are very pleased with the progress of our First-In-Man clinical study and we look forward to the forthcoming studies for our technology in the European markets" said Randy Werneth, CEO/President. "We have the ability in a matter of seconds to generate real-time 3D images of the heart with quality equivalent to a CT or MRI."

About Acutus MedicalSince June, 2011, Acutus Medical has pioneered a new and novel approach in the minimally invasive imaging and mapping of cardiac arrhythmias. 

Acutus Medical has concentrated its efforts on the developing its technology for the treatment of an aberrant arrhythmia, atrial fibrillation (AF). Acutus Medical believes that its technology may eventually play a significant role in improving the lives of countless individuals who are afflicted by AF.

This press release includes forward-looking statements regarding Acutus Medical Cardiac Imaging and Mapping Technology System. Any statement describing Acutus Medical's goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Acutus goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing products and in the endeavor of building a business around such products. Acutus Medical's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Acutus Medical forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Acutus Medical.  As a result, you are cautioned not to rely on these forward-looking statements.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs